International Alliance for
Biological Standardization

Maintaining the Quality of Vaccines Through the Use of Standards: Current Challenges and Future Opportunities

Library and Archives Canada, Ottawa, Canada

June 21-22, 2023

Sandra Prior, PhD

Principal Scientist

Medicines and Healthcare products Regulatory Agency (MHRA)

United Kingdom

E-mail: Sandra.prior@nibsc.org

Sandra Prior joined the National Institute for Biological Standards and Control (NIBSC), a center of the Medicines & Healthcare Products Regulatory Agency (MHRA, UK), in 2015. She works as a principal scientist in the Science, Research and Innovation group, investigating structure-function in relation to the safety and efficacy of monoclonal antibody products and developing international standards for biotherapeutic monoclonal antibodies, establishing the first WHO international standard for this type of biological medicines in 2017. She also contributes to vaccine immuno-monitoring and clinical assessment activities. She is a member of the European Directorate for the Quality of Medicines and HealthCare (EDQM) monoclonal antibody expert committee and the Official Medicines Control Laboratory (OMCL) monoclonal antibody testing group. She obtained her PhD from the University of Navarra (Spain) and moved to the UK, where she initially worked at NIBSC investigating safety and protective mechanisms of bacterial combination vaccines. In 2010, she joined Lonza Biologics (Cambridge, UK) working on bioactivity and immunogenicity assessment of candidate biotherapeutics. Sandra has over 20 years of experience in applied immunology and *in vitro* cell-based assay development.